Annovis Bio, Inc. (ANVS)
Pre-market:
| Previous close | 18.01 |
| Open | 18.00 |
| Bid | 0.00 x 1100 |
| Ask | 7.38 x 2200 |
| Day's range | 5.23 - 20.00 |
| 52-week range | 5.23 - 22.49 |
| Volume | |
| Avg. volume | 388,820 |
| Market cap | 80.237M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.23 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.40 |
- Reuters
UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study
Annovis Bio's on Monday reported data that showed its Alzheimer's disease drug failed to show statistical significance in meeting the goals of a mid-stage trial sending its shares tumbling as much as 60%. The trial tested the drug buntanetap in patients with mild-to-moderate Alzheimer's disease (AD) along two scales assessing cognition and cognitive dysfunction. In a press release, the company said a "post-hoc" analysis of the trial data had shown statistically significant results in improving cognition function scores along an Alzheimer's disease scale in a subgroup of patients who had mild disease and who tested positive for certain disease biomarkers.
GlobeNewswireAnnovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein levels are reduced, consistent with our previous Phase II biomarker dataBased on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying
ZacksWall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
